FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories
ESMO Breast highlights and expert commentary
FDA clearances reshape diagnostics and therapies
Liquid biopsy, mutations and treatment resistance
All Other Stories
Related Stories
Ultra‑sensitive ctDNA blood test could personalize breast cancer care for older women / 3 months
Grail names new CEO as Bob Ragusa retires / 3 months
ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 4 days
Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 29 days
Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 5 wks
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 6 wks
Liquid biopsy may speed childhood Burkitt lymphoma diagnosis in Africa / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cancer Screening, Long COVID, Hospital Operations, Olfaction and look for the RSS link.
StackHealth Time Machine